Strategy and Planning

For more than 27 years, I have been blessed to work with the same executive assistant. I know how long it’s been because Georgia started with me when my daughter, Ariel, was seven months old and, you guessed, she is now 27 (Ariel, that is).

This topic of “transition” came home to me (literally and figuratively) over the Thanksgiving holiday. With our adult kids returning, my husband and I decided it was time to have them go through their “bins” and throw out, donate, or take back with them, their childhood.

For those of you following closely (thank you!), you may recall that in an earlier e-conversation — 21st Century Commercialization — More than a Point in Time! — we defined commercialization as neither a function nor a process.

Ah, June, the season of life transitions — weddings, graduations, school progression and, with the year nearly half over, a reminder to reflect on where we have been and where we are going in 2019.

Back in the early 2000s, I was head of commercial strategy at Millennium Pharmaceuticals in Cambridge, Massachusetts. I remember saying to then CEO, Mark Levin, that we had an opportunity to define how the company vision, “Transcend the Limits of Medicine,” could be translated at the customer level.

Each month, you have given our team permission to communicate our views on the biopharma industry, its leadership, and overall commercialization of innovative medicines. We share this perspective with knowledge of a healthcare system based on what we read, hear, and know from personal experience.